Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HOPA 2018 | Immunotherapy options for NSCLC: nivolumab, pembrolizumab or atezolizumab?

Ross Camidge • 21 Mar 2018
HOPA 2018
Lung Cancer Non-Small Cell Lung Cancer Atezolizumab Nivolumab Pembrolizumab

How do you decide on which drug to use when treating non-small cell lung cancer (NSCLC) patients in a second-line setting? Here, speaking at the Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Ross Camidge, MD, PhD, of University of Colorado, Aurora, CO addresses the question of how to choose between nivolumab, pembrolizumab and atezolizumab for the treatment of NSCLC.

More from Ross Camidge

3:21
Hot topics in 2020: lung cancer
Ross Camidge • 26 Mar 2020
4:15
COVID-19 & treating patients with lung cancer
Ross Camidge • 26 Mar 2020
10:43
Updates in ALK+ NSCLC
Ross Camidge • 26 Mar 2020
1:30
Efficacy of lorlatinib in NSCLC post-second generation ALK TKI
Ross Camidge • 28 Sep 2019

Related Videos

2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
0:45
Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton • 18 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals